Protection against the mouse-adapted A/FM/1/47 strain of influenza A virus in mice by a monoclonal antibody with cross-neutralizing activity among H1 and H2 strains.
about
Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cellsCurrent and future antiviral therapy of severe seasonal and avian influenzaImmunoregulatory functions of immune complexes in vaccine and therapyInfluenza hemagglutinin stem-fragment immunogen elicits broadly neutralizing antibodies and confers heterologous protectionConserved epitopes of influenza A virus inducing protective immunity and their prospects for universal vaccine developmentDesign of an HA2-based Escherichia coli expressed influenza immunogen that protects mice from pathogenic challenge.Passive immunoprophylaxis and therapy with humanized monoclonal antibody specific for influenza A H5 hemagglutinin in miceAdvances in influenza vaccination.In silico structural homology modelling and docking for assessment of pandemic potential of a novel H7N9 influenza virus and its ability to be neutralized by existing anti-hemagglutinin antibodies.Hemagglutination inhibiting antibodies and protection against seasonal and pandemic influenza infectionPseudotype-based neutralization assays for influenza: a systematic analysis.Hemagglutinin Sequence Conservation Guided Stem Immunogen Design from Influenza A H3 SubtypeA potent broad-spectrum protective human monoclonal antibody crosslinking two haemagglutinin monomers of influenza A virusSafety and immunogenicity of multiple and higher doses of an inactivated influenza A/H5N1 vaccine.Association between Hemagglutinin Stem-Reactive Antibodies and Influenza A/H1N1 Virus Infection during the 2009 PandemicHeterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccineA cross-reactive neutralizing monoclonal antibody protects mice from H5N1 and pandemic (H1N1) 2009 virus infection.Human monoclonal antibodies broadly neutralizing against influenza B virus.Structural basis of influenza virus neutralization.Serial histopathological examination of the lungs of mice infected with influenza A virus PR8 strain.Targets for the induction of protective immunity against influenza a viruses.A human antibody recognizing a conserved epitope of H5 hemagglutinin broadly neutralizes highly pathogenic avian influenza H5N1 viruses.Hemagglutinin stalk antibodies elicited by the 2009 pandemic influenza virus as a mechanism for the extinction of seasonal H1N1 viruses.Passive immune neutralization strategies for prevention and control of influenza A infections.Antibodies against conserved antigens provide opportunities for reform in influenza vaccine designDesign of Escherichia coli-expressed stalk domain immunogens of H1N1 hemagglutinin that protect mice from lethal challenge.The prospects and challenges of universal vaccines for influenzaLaninamivir octanoate and artificial surfactant combination therapy significantly increases survival of mice infected with lethal influenza H1N1 Virus.Re-engaging cross-reactive memory B cells: the influenza puzzle.Cross-protective potential of a novel monoclonal antibody directed against antigenic site B of the hemagglutinin of influenza A viruses.Using monoclonal antibodies to prevent mucosal transmission of epidemic infectious diseases.A pan-H1 anti-hemagglutinin monoclonal antibody with potent broad-spectrum efficacy in vivoEpitope specificity of anti-HA2 antibodies induced in humans during influenza infectionProgress on adenovirus-vectored universal influenza vaccines.Mathematical Model Reveals the Role of Memory CD8 T Cell Populations in Recall Responses to Influenza.Masking of antigenic epitopes by antibodies shapes the humoral immune response to influenza.Interleukin-15 is critical in the pathogenesis of influenza a virus-induced acute lung injury.Prospects for universal influenza virus vaccine.Conformational stability of the hemagglutinin of H5N1 influenza A viruses influences susceptibility to broadly neutralizing stem antibodies.Broadly Reactive Human Monoclonal Antibodies Elicited following Pandemic H1N1 Influenza Virus Exposure Protect Mice against Highly Pathogenic H5N1 Challenge
P2860
Q21562507-6C52ED7C-7264-4392-8FF6-495A11D68F50Q24656164-9C91F948-B6CC-424F-A95C-A32DA5EBA558Q26738396-5C78756A-2466-4BFA-B0CE-BB3E7550A95CQ30209769-E4F58ECE-DDE2-459C-868F-875CB61A89BEQ30226873-23425BE0-E58B-4183-B163-8C1A40860027Q30227081-9F3328D9-6726-4F8D-AF8E-19568AF71F4CQ30357432-3978A44B-1916-4248-978C-75298FC05AD2Q30364315-3747C34E-C481-4DEC-8302-3E1650298F39Q30364943-9961AD4A-777F-42D7-9111-D027F3712657Q30366832-F9B0634C-B674-43C6-A789-0810D94F21DFQ30374662-517AA686-9B08-45C1-8865-2B353ACE505BQ30376605-0523F7EA-C9FC-4F81-861E-3BDB8ECC8B90Q30377012-8FD8CB2B-70E1-48B5-9355-E812914C33D7Q30378572-72F241B9-A7D1-44B4-AF0D-EA0102B75805Q30388004-1C78ABD8-419C-4C8E-83A0-C1C04504EAA0Q30388038-E6161142-04D0-406B-B538-5C8CDC16EB9BQ30393843-E114F668-C330-4794-BCC6-93D0FA7A506CQ30394240-933BB8D7-CEE1-4738-992E-853C76489678Q30398754-14385768-D06A-4171-98F6-860A4B6EC64AQ30404181-1C55971F-E169-4392-857D-A29B2D34910BQ30408100-8C10421C-8D5C-426A-84A4-9233D3F64DB2Q30411637-50150F61-8839-4FCB-B3FC-30B7892A337CQ30412616-DC0E1803-0C94-4706-AB5D-FB99BC218075Q30413158-8F9D7DF7-85F5-4C8F-802B-691871B2C7A4Q30416502-1A3B1549-9A3B-4F7D-AD80-736307F2A3CBQ30421687-02E30554-AC01-46CA-95AA-7E6FD3209A68Q30430703-3814316B-1798-444B-8FD6-9E66D03202E2Q31083146-66DBDE95-607C-43A8-8D0D-00F74C003664Q33353517-E33E4BD1-23AB-4134-AF92-191F0606CEACQ33419836-9A39B4B8-1505-47F9-84E7-1F2A5FFD6EAAQ33542433-2828DAF5-254A-455C-9DE9-87F53C029A0FQ36023093-63BBF600-E2F3-40AF-AC0E-9653B4690552Q37087170-3A090988-41D1-4F1E-A4C7-12E6950A2EEFQ38421971-CD515013-1CD8-44A7-95EF-EE58555BD792Q40652515-09502800-393C-42D3-8E00-B0351E031978Q40715214-B2023E23-5971-4414-9D18-F39A5D6E917BQ40756519-5CB7474D-3C88-4644-A63B-D77CAC718E3CQ41988078-F7698F9B-361B-4688-90E2-3E9484FC5583Q52625012-746110DC-070D-49B8-B3DC-3DD84A88FE46Q57094135-8A9F06CC-4780-4C09-8822-7793CC68EB5D
P2860
Protection against the mouse-adapted A/FM/1/47 strain of influenza A virus in mice by a monoclonal antibody with cross-neutralizing activity among H1 and H2 strains.
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
1994年论文
@zh
1994年论文
@zh-cn
name
Protection against the mouse-a ...... ivity among H1 and H2 strains.
@ast
Protection against the mouse-a ...... ivity among H1 and H2 strains.
@en
type
label
Protection against the mouse-a ...... ivity among H1 and H2 strains.
@ast
Protection against the mouse-a ...... ivity among H1 and H2 strains.
@en
prefLabel
Protection against the mouse-a ...... ivity among H1 and H2 strains.
@ast
Protection against the mouse-a ...... ivity among H1 and H2 strains.
@en
P2093
P2860
P1433
P1476
Protection against the mouse-a ...... tivity among H1 and H2 strains
@en
P2093
P2860
P304
P407
P577
1994-01-01T00:00:00Z